ABT tried the same kind of “overpowering” pooling ploy with Xinlay, but it didn’t fool anyone on the FDA advisory panel (#msg-7720638) nor did it fool anyone at the FDA itself.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”